Programs

Our fearless pursuit of science, guided by in-depth translational research, aims to address unmet needs for patients with limited treatment options.

Our fearless pursuit of science, guided by in-depth translational research, aims to address unmet needs for patients with limited treatment options.

KRAS Inhibitors
KRAS Inhibitors

The journey to create a KRAS inhibitor has been actively ongoing for over three decades.1,2 However, breakthroughs are on the horizon and our experienced team is rigorously advancing discovery and development programs targeting the KRAS G12C and KRAS G12D mutations.

Sitravatinib
Sitravatinib

Checkpoint inhibitors have revolutionized the cancer treatment landscape helping many people with different types of cancer live longer. Over time, checkpoint inhibitors stop working in many patients, leaving them with few remaining treatment options.

Our research is investigating whether novel combination approaches will augment checkpoint inhibitor therapy by targeting key pathways and cell types responsible for tumor growth and immune suppression in the tumor microenvironment.